EPS for Revance Therapeutics, Inc. (RVNC) Expected At $-0.69 on May, 8

April 17, 2018 - By Robert Reynolds

During Q4 2017 the big money sentiment increased to 2.8. That’s change of 1.80, from 2017Q3’s 1. 6 investors sold all, 19 reduced holdings as Revance Therapeutics, Inc. ratio increased. 39 rose positions while 31 funds took positions. Funds hold 31.34 million shares thus 15.17% more from 2017Q3’s 27.21 million shares.
Geode Mgmt Lc holds 0% or 219,561 shs in its capital. Pnc Fincl Gru Incorporated stated it has 0% in Revance Therapeutics, Inc. (NASDAQ:RVNC). Bnp Paribas Arbitrage owns 0% invested in Revance Therapeutics, Inc. (NASDAQ:RVNC) for 4,849 shs. Jane Street Gp Ltd reported 19,172 shs. Moreover, Voya Mngmt Ltd has 0% invested in Revance Therapeutics, Inc. (NASDAQ:RVNC) for 10,392 shs. 182,580 are owned by Rhenman Asset Mngmt. Blair William And Il holds 0% or 12,950 shs in its capital. Tekla Cap Mgmt Limited Liability reported 32,225 shs or 0.04% of all its holdings. 26,546 were accumulated by Goldman Sachs Grp Inc. State Street holds 461,360 shs or 0% of its capital. Tower Research Cap Ltd Liability Com (Trc) stated it has 46 shs or 0% of all its holdings. Legal General Gru Public Limited holds 0% of its capital in Revance Therapeutics, Inc. (NASDAQ:RVNC) for 5,806 shs. Federated Invsts Inc Pa accumulated 38,285 shs. Teacher Retirement Systems Of Texas invested 0% of its capital in Revance Therapeutics, Inc. (NASDAQ:RVNC). Northern Tru Corp invested in 301,405 shs or 0% of the stock.

Revance Therapeutics, Inc. had 6 sales and 1 insider buy since October 18, 2017. This’s net activity of $2.77 million. On Wednesday, March 7 20,000 shs were sold by SILVERNAIL LAUREN P, worth $640,000. GARDNER PHYLLIS sold 5,333 shs worth $168,045. $98,393 worth of Revance Therapeutics, Inc. (NASDAQ:RVNC) was bought by Vickers Philip J..

Revance Therapeutics, Inc. (NASDAQ:RVNC)’s earnings report is awaited On May, 8., Faxor reports. Analysts have expectation on stock’s EPS of $-0.69. That’s up 26.60 % from last year’s $-0.94 EPS. Last quarter $-1.14 EPS was reported. Analysts forecasts -39.47 % EPS growth this quarter. RVNC reached $32.25 on during the last trading session after $0.5 change.Currently Revance Therapeutics, Inc. is uptrending after 51.24% change in last April 17, 2017. RVNC has also 186,049 shares volume. RVNC outperformed by 39.69% the S&P500.

Revance Therapeutics, Inc. (NASDAQ:RVNC) Ratings Coverage

Total analysts of 9 have positions in Revance Therapeutics (NASDAQ:RVNC) as follows: 8 rated it a “Buy”, 0 with “Sell” and 1 with “Hold”. The positive are 89%. Since October 24, 2017 according to StockzIntelligence Inc Revance Therapeutics has 19 analyst reports. The company rating was maintained by Cantor Fitzgerald on Thursday, November 2. In Friday, December 8 report SunTrust maintained the stock with “Buy” rating. On Thursday, April 12 the firm earned “Buy” rating by Cantor Fitzgerald. On Thursday, March 1 Piper Jaffray maintained the shares of RVNC in report with “Buy” rating. On Tuesday, December 5 the stock of Revance Therapeutics, Inc. (NASDAQ:RVNC) earned “Buy” rating by Guggenheim. On Monday, November 27 the firm earned “Buy” rating by Barclays Capital. On Thursday, November 16 Cantor Fitzgerald maintained the shares of RVNC in report with “Buy” rating. On Thursday, January 4 the firm has “Buy” rating by Guggenheim given. On Tuesday, December 5 the stock of Revance Therapeutics, Inc. (NASDAQ:RVNC) has “Buy” rating given by Piper Jaffray. On Wednesday, December 13 the stock has “Buy” rating by Cantor Fitzgerald.

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications.The company has $1.19 billion market cap. The company's lead drug candidate is DaxibotulinumtoxinA for injection , which is in Phase III clinical trials to treat glabellar (frown) lines, as well as in Phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis.Last it reported negative earnings. It is also developing DaxibotulinumtoxinA topical gel (RT001) that is in preclinical development.

Revance Therapeutics, Inc. (NASDAQ:RVNC) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.